Trial reportTranslational psychiatry2016
Dopamine D2/3- and μ-opioid receptor antagonists reduce cue-induced responding and reward impulsivity in humans.
Trial report in Translational psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Differential Associations of Dopamine and Serotonin With Reward and Punishment Processes in Humans: A Systematic Review and Meta-Analysis.JAMA psychiatry · 2025Pooled it
- A multinational analysis of how emotions relate to economic decisions regarding time or risk.Nature human behaviour · 2024Pooled it
- Dopamine and Temporal Discounting: Revisiting Pharmacology and Individual Differences.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Trial
- Dopamine has no direct causal role in the formation of treatment expectations and placebo analgesia in humans.PLoS biology · 2024Trial
- Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards.Human brain mapping · 2024Trial
- Facial mimicry is not modulated by dopamine D2/3 and opioid receptor antagonism.Psychopharmacology · 2023Trial
- The catecholamine precursor Tyrosine reduces autonomic arousal and decreases decision thresholds in reinforcement learning and temporal discounting.PLoS computational biology · 2022Trial
- Trial
- The role of oxytocin in delay of gratification and flexibility in non-social decision making.eLife · 2021Trial
- Activation of D1 receptors affects human reactivity and flexibility to valued cues.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- Effects of opioid receptor stimulation and blockade on touch pleasantness: a double-blind randomised trial.Social cognitive and affective neuroscience · 2019Trial
- Dopamine Receptor-Specific Contributions to the Computation of Value.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Trial
- Balancing Risk and Reward: Dopamine's Central Role in Economic Decision-Making.Brain sciences · 2025Review
- Striatal cue-reactivity and neurotransmitter function in gambling disorder.Journal of behavioral addictions · 2025Article
- About Sugar Addiction.Brain and behavior · 2025Review
- Opioid Regulation of Social Homeostasis: Connecting Loneliness to Addiction.Biological psychiatry · 2025Review
- Neural reward system reflects individual value comparison strategy in cost-benefit decisions.Communications biology · 2024Article
- The Role of Dopamine in Impulsivity and Substance Abuse: A Narrative Review.Health psychology research · 2024Article
- Naltrexone engages a brain reward network in the presence of reward-predictive distractor stimuli in males.Addiction neuroscience · 2023Article
- Profiling transcriptomic responses of human stem cell-derived medium spiny neuron-like cells to exogenous phasic and tonic neurotransmitters.Molecular and cellular neurosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased responding to drug-associated stimuli (cue reactivity) and an inability to tolerate delayed gratification (reward impulsivity) have been implicated in the development and maintenance of drug addiction. Whereas data from animal studies suggest that both the dopamine and opioid system are involved in these two reward-related processes, their role in humans is less clear. Moreover, dopaminergic and opioidergic drugs have not been directly compared with regard to these functions, even though a deeper understanding of the underlying mechanisms might inform the development of specific treatments for elevated cue reactivity and reward impulsivity. In a randomized, double-blind, between-subject design we administered the selective dopamine D2/D3 receptor antagonist amisulpride (400 mg, n=41), the unspecific opioid receptor antagonist naltrexone (50 mg, n=40) or placebo (n=40) to healthy humans and measured cue-induced responding with a Pavlovian-instrumental transfer task and reward impulsivity with a delay discounting task. Mood was assessed using a visual analogue scale. Compared with placebo, amisulpride significantly suppressed cue-induced responding and reward impulsivity. The effects of naltrexone were similar, although less pronounced. Both amisulpride and naltrexone decreased average mood ratings compared with placebo. Our results demonstrate that a selective blockade of dopamine D2/D3 receptors reduces cue-induced responding and reward impulsivity in healthy humans. Antagonizing μ-opioid receptors has similar effects for cue-induced responding and to a lesser extent for reward impulsivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.